You followed your doctor’s advice. You took the medications as prescribed, waited the six weeks for them to work, managed the side effects, adjusted the doses. And yet – nothing changed. Or perhaps things improved briefly, then the darkness returned.

If this sounds familiar, you are not failing at treatment. You may be living with treatment-resistant depression (TRD) – one of the most misunderstood and underserved conditions in Canadian mental health care.

This guide explains what TRD is, why it happens, what the Canadian clinical guidelines say, and what treatment options now exist – including rapid-acting approaches that are changing outcomes for patients who had run out of hope.

What Is Treatment-Resistant Depression?

Treatment-resistant depression is defined clinically as a major depressive episode that has not responded to at least two different antidepressant medications, each tried at an adequate dose for an adequate duration (typically six to eight weeks).

It is not a character flaw, a lack of effort, or a sign that treatment can never work. It is a recognized clinical condition affecting approximately 22% of all Canadians diagnosed with major depressive disorder (MDD). That means more than one in five people receiving standard care for depression are not getting adequate relief.

Why Do Standard Antidepressants Fail for Some People?

Most conventional antidepressants work on the serotonin, norepinephrine, or dopamine systems – neurotransmitter pathways that are well-understood but don’t explain every case of depression. For patients with TRD, research increasingly points to other biological factors:

•  Glutamate dysregulation – abnormalities in the brain’s primary excitatory neurotransmitter system, which conventional antidepressants don’t address

•  Reduced neuroplasticity – a diminished ability of the brain to form new connections, which may underlie the persistent cognitive and emotional symptoms of TRD

•  Inflammatory pathways – elevated inflammatory markers are found in a significant subset of patients with depression unresponsive to standard treatment

•  Genetic variations in drug metabolism (pharmacogenomics) that reduce the effectiveness of specific medications for specific individuals

This is why simply trying another SSRI is often not the answer for TRD. The underlying biology requires a different therapeutic approach.

The Canadian Clinical Landscape for TRD

The Canadian Network for Mood and Anxiety Treatments (CANMAT 2023) explicitly recognizes rapid-acting infusion therapy as a third-line treatment for adults with treatment-resistant depression. This means it is an officially guideline-recommended option for patients who have not responded to at least two prior treatments.

Health Canada has also approved intranasal esketamine (Spravato) specifically for treatment-resistant depression.

For the majority of TRD patients, however, intravenous infusion therapy delivers the most robust, rapid, and well-documented response.

What Rapid-Acting Infusion Therapy Means for TRD Patients

The most significant clinical feature of infusion-based treatment for TRD is speed. Where conventional antidepressants require four to six weeks to produce measurable effects, infusion therapy can produce meaningful reductions in depressive symptoms – including suicidal ideation – within hours to days of the first treatment.

Multiple randomized controlled trials and meta-analyses have confirmed this rapid-acting antidepressant effect (Murrough et al., 2013). In real-world Canadian clinical settings, including Braxia Health’s clinic where over 30,000 treatments have been delivered, the majority of patients report significant improvement following their initial six-session induction series.

Who Qualifies for TRD Treatment at Braxia Health?

Braxia Health accepts patients with a confirmed or probable diagnosis of treatment-resistant depression who meet the following criteria:

•  Documented history of two or more failed antidepressant trials

•  A referral from a community healthcare provider (family physician, psychiatrist, nurse practitioner)

•  No contraindications identified in the medical screening process

•  Commitment to the full induction series and follow-up care

Patients with bipolar depression, PTSD, and OCD may also qualify – assessed individually by a Braxia physician.

What the Treatment Journey Looks Like

A typical TRD treatment journey at Braxia Health unfolds across three phases:

•  Assessment and onboarding (Week 1): Intake appointment, medical screening, informed consent, treatment planning.

•  Induction series (Weeks 2–7): Six treatment sessions delivered over four to six weeks by an anesthesiologist. Each session is monitored 1:1 by a registered nurse. Many patients notice improvement by sessions three or four.

•  Maintenance and follow-up (Ongoing): Monthly or bimonthly maintenance sessions tailored to sustain response. Integration with your existing mental health care team.

For patients who benefit from psychotherapeutic support alongside their treatment, Braxia’s in-house psychotherapists offer psychedelic-assisted psychotherapy (PAP) – a structured model that uses the therapeutic window created by infusion therapy to support deeper psychological processing and integration.

You Have Not Run Out of Options

Treatment-resistant depression is one of the most difficult conditions in psychiatry – but it is not untreatable. The emergence of rapid-acting, neuroplasticity-targeted therapies represents a genuine clinical breakthrough for the patients conventional medicine had left behind.

At Braxia Health, we have worked with thousands of patients who came to us after years – sometimes decades – of inadequate treatment. Many have found meaningful, lasting relief through our programs.

If you or someone you love has not responded to standard antidepressant treatment, ask your doctor about a referral to Braxia Health. Our intake team is also available to answer questions before your first appointment.

Braxia Health, Mississauga, Ontario. Virtual consultations available across Ontario (other provinces coming soon). Veterans may have coverage through their benefits. WSIB patients may have coverage depending on their claim.

This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any decisions about your treatment.